HERBICIDE ADJUVANTS COMPENDIUM OF th Edition PPP-115 WS-54

4 stars based on 65 reviews

The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method. This invention relates to methods for the delivery of pharmaceutical compounds to the inner ear for the treatment of tinnitus induced by cochlear excitotoxicity.

Specifically, this invention relates to the local administration of N-Methyl-D-Aspartate NMDA receptor antagonists to the inner ear to suppress the NMDA receptor mediated aberrant activity of the auditory nerve following acute, unifast trad liquid msds ethanol or prolonged or chronic occurrences of cochlear excitotoxicity provoked by incidents such as acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more certain ototoxic medications or sudden deafness and thus, block tinnitus in the case of such incidents.

Tinnitus, the perception of sound without external acoustic stimulation, is a very common inner ear disorder. It is estimated that 8.

In spite of the high prevalence of tinnitus unifast trad liquid msds ethanol its severe impact on the health and quality of life of people affected by it, there is no truly effective treatment available.

Current therapy approaches include the avoidance of ototoxic medications, reduced consumption of alcohol, caffeine and nicotine, reduced stress, the use of background noises or wearable tinnitus maskers some in combination with hearing aidsbehavioral therapies such as hypnosis, cognitive therapy and biofeedback, tinnitus retraining therapy TRTpharmacological and other complementary therapies. Tinnitus is not a disease, but rather a symptom common to various hearing unifast trad liquid msds ethanol, just as pain accompanies many different illnesses.

Other, less frequent origins include exposure to ototoxic drugs aminoglycoside antibiotics, high-dose loop diuretics, nonsteroidal anti-inflammatory drugs and certain chemotherapeutic agentsreduced vascular flow ischemiaautoimmune processes, infectious diseases, conductive hearing loss, otosclerosis, head trauma etc. Over the past decade, major advances in the research of the physiopathology of the inner ear resulted in the identification unifast trad liquid msds ethanol the key role of the inner hair cell synaptic complex in the development of tinnitus induced by cochlear excitotoxicity, one of the most frequent triggers of tinnitus.

Excitotoxicity, which was first described by Olney et al. It activates postsynaptic glutamate receptors ionotropic and metabotropicwhich leads to depolarization and neuronal excitation. However, if receptor activation becomes excessive by an excessive release of glutamate as in the case of excitotoxicity, the target neurons are damaged and may eventually die Puel J.

In all cases, excitotoxicity is characterized by a two-step mechanism: Within the next 5 days, synaptic repair neo-synaptogenesis is observed with a full or partial recovery of cochlear potentials Puel et al.

Cochlear excitotoxicity may induce tinnitus during the process of rupturing of the postsynaptic structures and, provided the rupture is not terminal, the following neo-synaptogenesis at the inner hair cell synaptic complex Puel et al. A key role in functional recovery after excitotoxicity is played by the NMDA receptors, which are not involved in the activity of auditory nerve fibres under physiological conditions Puel et al.

As could be shown in an animal model of cochlear synaptic repair mechanisms, blockage of the NMDA receptors by local administration of the NMDA receptor antagonist D-AP5 delayed the functional recovery and the regrowth of auditory dendrites Gervais D'Aldin et al. It could thus be concluded that glutamate, in addition to its role as a fast excitatory neurotransmitter, has a neurotrophic role via the activation of NMDA receptors.

During the process of neo-synaptogenesis afferent dendrites are in a critical state, and may thus be particularly susceptible to excitation by the activation of the NMDA receptors. To avoid unifast trad liquid msds ethanol such aberrant excitation, and therefore tinnitus, which may well continue infinitely due to incomplete neo-synaptogenesis, unifast trad liquid msds ethanol therapeutic strategy would thus seek to specifically antagonize NMDA receptors.

As has been demonstrated, the local administration of NMDA receptor antagonists to the cochlea prevents excitotoxicity induced by acoustic trauma or ischemia Duan et al. While excitotoxicity could also be blocked by application of 2-amino 3-hydroxymethylisoxazolyl propionate AMPA or kainate receptor antagonists, as the acute swelling of afferent dendrites primarily occurs via them Puel et al.

As fast excitatory neurotransmission between the inner hair cells and the auditory nerve fibres is predominantly mediated by AMPA preferring receptors Ruel et al. The hypothesized implication of NMDA receptors in the generation of tinnitus has so far only been tested and demonstrated in vivo with a behavioral model of salicylate-induced tinnitus Guitton et al. The behavioral model, which had to be developed to measure tinnitus, as tinnitus is not directly observable, was based on the active avoidance paradigm: Administration of salicylate led to a significant increase in the number of jumps even in the absence of external sound false positivesindicating the perception of tinnitus.

Following delivery of the NMDA antagonists MK, 7-CK and gacyclidine to the animals' cochleas via the round window membrane the number of unifast trad liquid msds ethanol positives decreased significantly, indicating the suppression of tinnitus.

While these results provided for the first time a confirmation of the hypothesized implication of NMDA receptors in the occurrence of tinnitus, they could clearly not be generalized for all kinds of this inner ear disorder, as salicylate-induced tinnitus is a very peculiar form of tinnitus. Salicylate, the active component of aspirin, has been known for more than a century to induce tinnitus if taken in large doses Cazals Y.

It may provoke similar sensations of tinnitus as in the case of cochlear excitotoxicity or other cases with different origin, but it is usually reversible and based on a specific molecular mechanism.

Application of mefenamate, a well known cyclooxygenase inhibitor, instead of salicylate also increased the number of false positive responses, suggesting that salicylate-induced tinnitus is related to an inhibition of cyclooxygenase pathway.

While tinnitus induced by cochlear excitotoxicity is the result of a cascade of glutamate mediated processes leading to the up-regulation of mRNA of NMDA receptors, salicylate-induced tinnitus is mediated by changes in the arachidonic acid metabolism see e. Salicylate has been shown to inhibit cyclooxygenase activity see e.

Vane and Botting, Am. Electrophysiological studies have demonstrated that arachidonic acid increases the channel opening probability of NMDA receptor in various systems, including cerebellar granule cells, dissociated pyramidal cells, cortical neurons, and adult hippocampal slices see e.

Unlike tinnitus induced by excitotoxicity, there is thus no morphological damage to the inner hair cell synaptic complex, and in particular to the synaptic ending, involved in salicylate-induced tinnitus. Its neuroprotective properties in the case of glutamate excitotoxicity are demonstrated in cell culture.

However, the unifast trad liquid msds ethanol pharmacological action and efficacy under pathophysiological conditions in vivo are not shown, i. This must be considered a serious deficiency given the complexities of the inner hair cell synaptic complex.

In addition, Sands teaches oral administration of the NMDA receptor antagonist, while discussing topical administration only for cases where a patient is unable to swallow or the oral route of administration is otherwise impaired. Systemic administration of NMDA receptor antagonists to treat inner ear disorders is usually ineffective, as the cochlea is protected like unifast trad liquid msds ethanol brain by a biological barrier.

Relatively high doses to achieve a desired therapeutic effect would thus be required, but various potent side effects of NMDA receptor antagonists such as reduced learning, memory or motility significantly restrict the maximum tolerable doses.

As various studies with humans for the treatment of CNS disorders by NMDA receptor antagonists have shown, plasma levels after systemic administration were consistently unifast trad liquid msds ethanol those needed for maximal neuroprotection in animal models, as clinical doses had to be limited due to a number of potentially adverse CNS effects, catatonia, increased blood pressure and anaesthesia Kemp and McKernan, Nature Neuroscience unifast trad liquid msds ethanol, supplement: On the other hand, it has been shown that local administration of the NMDA-AMPA receptor antagonist caroverine to the inner ear results in higher intracochlear concentrations, while avoiding high secondary concentrations in plasma and cerebrospinal fluid as seen with systemic administration Chen et al.

The inventors cite results from a clinical study with systemic unifast trad liquid msds ethanol which showed a reduction in tinnitus during treatment.

Hypotheses brought forward to explain the results obtained centre on outer hair cells and the presynapse, and do not specifically cover the role of NMDA receptors. While there are several indications supporting the hypothesis that NMDA receptors play an important role in the genesis of tinnitus induced by cochlear excitotoxicity, the foregoing discussion shows that the molecular mechanisms are still unclear, and that it is therefore not possible to predict reliably whether the use of NMDA receptor antagonists will effectively block this particular type of tinnitus.

Further pathophysiological studies on the generation of tinnitus are thus required to validate the hypothesis and develop specific and truly effective therapeutic strategies.

The methods include administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist. In a method for treating tinnitus, the NMDA receptor antagonist administered is effective to suppress or reduce Unifast trad liquid msds ethanol receptor mediated aberrant activity of the auditory nerve in the human in need of such treatment.

In a method for preventing tinnitus, the NMDA receptor antagonist administered is effective to prevent NMDA receptor mediated aberrant activity of the auditory nerve in the human in need of such treatment. The present invention also relates to novel methods for the screening of compounds for the treatment and prevention of tinnitus wherein the method utilizes an electrophysiological method of measuring and quantifying the extent of tinnitus.

The methods include the administration to a test animal of a unifast trad liquid msds ethanol compound wherein the test animal, for example, comprises an electrode in contact with the round window membrane of the ear. The electrode is used to measure the ensemble spontaneous activity ESA of the ear where a spectral peak at about to Hz is indicative of tinnitus. The administration of test unifast trad liquid msds ethanol to the animal, to the round window membrane or to the inner ear is embodied in the present invention.

The animal may have acquired tinnitus by, for example, acustic trama, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, unifast trad liquid msds ethanol deafness, or other equivalent cochlear excitotoxic-inducing occurrence. Hearing loss induced by acoustic trauma was assessed by recording CAP measurements unifast trad liquid msds ethanol days after trauma. A Acoustic trauma led to a decrease in correct behavioral responses to sound stimulation, followed by partial recovery over time, reflecting the induced hearing loss.

B The number of false positives differed substantially among tested animals following acoustic trauma. Group 1 animals did not experience tinnitus, group 2 animals experienced tinnitus only transiently, while group 3 animals experienced tinnitus both transiently and then permanently. Treatment with D-JNKI-1 prevented hearing loss after acute acoustic trauma, as shown by the rapid recovery of score following trauma A unifast trad liquid msds ethanol had no significant effect on the prevention of tinnitus, as the prevalence and patterns of tinnitus were essentially the same as in untreated animals B.

A The average behavioral score dropped from day 0 to day 1 and recovered subsequently; however improvement was slower than in untreated animals. B Local administration of the NMDA antagonist 7-CK resulted in suppressing persistent tinnitus induced by cochlear excitotoxicity; only cases of transient tinnitus could be observed. A The average behavioral score dropped from day 0 to day 1 and recovered subsequently ; however improvement was slower than in untreated animals.

The stereocilia of OHC and IHC remain intact following salicylate injections over 2 days 6 Awhile those animals which were exposed to acoustic trauma display severe damage unifast trad liquid msds ethanol OHC stereociliary bundles as well as disarrayed and in some cases even fused indicated by black arrowhead IHC stereocilia 6 D.

Low magnification of the IHC synaptic complex shows no ultrastructural abnormalities in case of the salicylate treatment 6 Bwhereas in traumatized animals a massive and dramatic swelling indicated by asterisks of the radial afferent dendrites can be seen at the basal pole of the IHC in the affected frequency range area, confirming that excitotoxicity has occurred 6 E.

Note the presence of numerous vacuoles in the apical part of the IHC and abnormally shaped stereocilia indicated by arrowhead. High magnification of unifast trad liquid msds ethanol basal IHC pole shows again no anomalies for the salicylate treated animal 6 C. The two afferent nerve endings indicated by a1 and a2 are normal, and a characteristic presynaptic body facing afferent a2 is clearly visible.

Contrary to this, 6 F displays swollen al and disrupted a2 nerve endings and the presynaptic body facing a2. Immunoblots from the brain of control animals were performed to verify that the molecular weight of the NR1 subunit is identical in both brain and cochlea. A shows the permanent threshold shift PTS of the auditory function resulting from the exposure to noise at the beginning of the experiment.

B shows the ESA recording just prior to the exposure of the animal to dB of sound at 6 kHz during 40 minutes. Note the spectral peak centered at around Hz to 1 kHz which is indicative of a normal hearing activity. Unifast trad liquid msds ethanol shows the ESA recording 5 days after the noise exposure on T0. Note the spectral peak in the to frequency range, unifast trad liquid msds ethanol is indicative of the presence of tinnitus. This peak had appeared immediately after the noise trauma and persisted from then on in a stable unifast trad liquid msds ethanol.

The regular unifast trad liquid msds ethanol peak, however, had disappeared and subsequently recovered. The contralateral ear showed exactly the same pattern of ESA with a peak at to Hz, indicating also the presence of tinnitus. Following these measurements, the animal unifast trad liquid msds ethanol treated on T0 with the NMDA antagonist Ketamine by local administration onto the round window membrane.

D On the day following treatment administration T1the ESA recording for the treated ear showed the absence of the to Hz spectral peak, indicating unifast trad liquid msds ethanol successful suppression of unifast trad liquid msds ethanol. The regular peak centered at Hz to 1 kHz still appeared, yet diminished. In the contralateral ear, tinnitus was still measured. In addition, the regular peak centered at around Hz to 1 kHz had fully recovered.

F In the untreated left ear, the presence of tinnitus was still indicated by the ESA recording. Please note that the PTS was not changed by the treatment Ai. The present invention is based on experimental findings with an animal model of tinnitus induced by cochlear excitotoxicity.

The invention relates to the use of pharmaceutical compounds that act specifically as NMDA receptor antagonists. While not wishing to be bound by theory, it is believed that an NMDA receptor antagonist of the present invention binds to the NMDA receptor at one of its various binding sites, thereby blocking partly or entirely the opening of the receptor's ion channel.

The NMDA receptor is activated in a complex manner such that both glutamate and glycine binding are required to open the ion channel and permit calcium entry Kemp and McKernan, Nature Neuroscience 5, supplement: Glutamate has the neurotransmitter role, as it is released from presynaptic terminals in an activity-dependent manner, whereas glycine acts as a modulator, which is present in the extracellular fluid at more constant levels.

The ion-channel integral to the NMDA receptor is voltage-dependently blocked by magnesium, and depolarization removes this block. Binding of an NMDA receptor antagonist to either of the three antagonist sites results in partial or complete blockage of the NMDA receptor and hence blocks or reduces the opening of the ion channel and depolarization of the neuron. The NMDA receptor antagonist thus suppresses the aberrant excitation of the auditory nerve through up-regulated NMDA receptors which may follow cochlear excitotoxicity and thus also reduces or eliminates the perception of tinnitus.

By targeting specifically NMDA receptors, which are only up-regulated under pathophysiological conditions, to suppress the NMDA receptor mediated aberrant activity of the auditory nerve, undesired side-effects on hearing can unifast trad liquid msds ethanol avoided, as normal auditory neurotransmission is primarily mediated by AMPA receptors.

In one embodiment, the invention relates to a method for treating tinnitus induced by cochlear excitotoxicity in a human. The method comprises administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist. The NMDA receptor antagonist is administered in an amount and for a period of time, effective to suppress or reduce NMDA receptor-mediated aberrant activity of the auditory nerve in a human in need of such treatment.

Guadagnare bitcoin online exchange

  • Simon hausdorff bitcoin charts

    Virtual currency following the bitcoin trailer

  • 65 nm asic bitcoin mining chip motherboard review

    Earn 1 free bitcoin

Bitcoin market value graphic

  • How to buy bitcoin with paypal 2017 best method

    Top 20 alternative apps to winkdexbitcoin price index for iphone

  • Meet dash and dot robots australia

    Blockchain weapon repairs

  • Yobit exchange wiki

    Bitstamp application letters

Bitcoin price chart 2011 chevrolet

46 comments Bitcoin mining machine 2016 camaro

Why hexabot went down the power of bitcoin

The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method. This invention relates to methods for the delivery of pharmaceutical compounds to the inner ear for the treatment of tinnitus induced by cochlear excitotoxicity.

Specifically, this invention relates to the local administration of N-Methyl-D-Aspartate NMDA receptor antagonists to the inner ear to suppress the NMDA receptor mediated aberrant activity of the auditory nerve following acute, repeated or prolonged or chronic occurrences of cochlear excitotoxicity provoked by incidents such as acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more certain ototoxic medications or sudden deafness and thus, block tinnitus in the case of such incidents.

Tinnitus, the perception of sound without external acoustic stimulation, is a very common inner ear disorder. It is estimated that 8. In spite of the high prevalence of tinnitus and its severe impact on the health and quality of life of people affected by it, there is no truly effective treatment available. Current therapy approaches include the avoidance of ototoxic medications, reduced consumption of alcohol, caffeine and nicotine, reduced stress, the use of background noises or wearable tinnitus maskers some in combination with hearing aids , behavioral therapies such as hypnosis, cognitive therapy and biofeedback, tinnitus retraining therapy TRT , pharmacological and other complementary therapies.

Tinnitus is not a disease, but rather a symptom common to various hearing disorders, just as pain accompanies many different illnesses. Other, less frequent origins include exposure to ototoxic drugs aminoglycoside antibiotics, high-dose loop diuretics, nonsteroidal anti-inflammatory drugs and certain chemotherapeutic agents , reduced vascular flow ischemia , autoimmune processes, infectious diseases, conductive hearing loss, otosclerosis, head trauma etc.

Over the past decade, major advances in the research of the physiopathology of the inner ear resulted in the identification of the key role of the inner hair cell synaptic complex in the development of tinnitus induced by cochlear excitotoxicity, one of the most frequent triggers of tinnitus. Excitotoxicity, which was first described by Olney et al. It activates postsynaptic glutamate receptors ionotropic and metabotropic , which leads to depolarization and neuronal excitation.

However, if receptor activation becomes excessive by an excessive release of glutamate as in the case of excitotoxicity, the target neurons are damaged and may eventually die Puel J. In all cases, excitotoxicity is characterized by a two-step mechanism: Within the next 5 days, synaptic repair neo-synaptogenesis is observed with a full or partial recovery of cochlear potentials Puel et al.

Cochlear excitotoxicity may induce tinnitus during the process of rupturing of the postsynaptic structures and, provided the rupture is not terminal, the following neo-synaptogenesis at the inner hair cell synaptic complex Puel et al. A key role in functional recovery after excitotoxicity is played by the NMDA receptors, which are not involved in the activity of auditory nerve fibres under physiological conditions Puel et al.

As could be shown in an animal model of cochlear synaptic repair mechanisms, blockage of the NMDA receptors by local administration of the NMDA receptor antagonist D-AP5 delayed the functional recovery and the regrowth of auditory dendrites Gervais D'Aldin et al. It could thus be concluded that glutamate, in addition to its role as a fast excitatory neurotransmitter, has a neurotrophic role via the activation of NMDA receptors.

During the process of neo-synaptogenesis afferent dendrites are in a critical state, and may thus be particularly susceptible to excitation by the activation of the NMDA receptors. To avoid any such aberrant excitation, and therefore tinnitus, which may well continue infinitely due to incomplete neo-synaptogenesis, a therapeutic strategy would thus seek to specifically antagonize NMDA receptors.

As has been demonstrated, the local administration of NMDA receptor antagonists to the cochlea prevents excitotoxicity induced by acoustic trauma or ischemia Duan et al. While excitotoxicity could also be blocked by application of 2-amino 3-hydroxymethylisoxazolyl propionate AMPA or kainate receptor antagonists, as the acute swelling of afferent dendrites primarily occurs via them Puel et al. As fast excitatory neurotransmission between the inner hair cells and the auditory nerve fibres is predominantly mediated by AMPA preferring receptors Ruel et al.

The hypothesized implication of NMDA receptors in the generation of tinnitus has so far only been tested and demonstrated in vivo with a behavioral model of salicylate-induced tinnitus Guitton et al. The behavioral model, which had to be developed to measure tinnitus, as tinnitus is not directly observable, was based on the active avoidance paradigm: Administration of salicylate led to a significant increase in the number of jumps even in the absence of external sound false positives , indicating the perception of tinnitus.

Following delivery of the NMDA antagonists MK, 7-CK and gacyclidine to the animals' cochleas via the round window membrane the number of false positives decreased significantly, indicating the suppression of tinnitus. While these results provided for the first time a confirmation of the hypothesized implication of NMDA receptors in the occurrence of tinnitus, they could clearly not be generalized for all kinds of this inner ear disorder, as salicylate-induced tinnitus is a very peculiar form of tinnitus.

Salicylate, the active component of aspirin, has been known for more than a century to induce tinnitus if taken in large doses Cazals Y.

It may provoke similar sensations of tinnitus as in the case of cochlear excitotoxicity or other cases with different origin, but it is usually reversible and based on a specific molecular mechanism.

Application of mefenamate, a well known cyclooxygenase inhibitor, instead of salicylate also increased the number of false positive responses, suggesting that salicylate-induced tinnitus is related to an inhibition of cyclooxygenase pathway. While tinnitus induced by cochlear excitotoxicity is the result of a cascade of glutamate mediated processes leading to the up-regulation of mRNA of NMDA receptors, salicylate-induced tinnitus is mediated by changes in the arachidonic acid metabolism see e.

Salicylate has been shown to inhibit cyclooxygenase activity see e. Vane and Botting, Am. Electrophysiological studies have demonstrated that arachidonic acid increases the channel opening probability of NMDA receptor in various systems, including cerebellar granule cells, dissociated pyramidal cells, cortical neurons, and adult hippocampal slices see e.

Unlike tinnitus induced by excitotoxicity, there is thus no morphological damage to the inner hair cell synaptic complex, and in particular to the synaptic ending, involved in salicylate-induced tinnitus. Its neuroprotective properties in the case of glutamate excitotoxicity are demonstrated in cell culture. However, the compound's pharmacological action and efficacy under pathophysiological conditions in vivo are not shown, i. This must be considered a serious deficiency given the complexities of the inner hair cell synaptic complex.

In addition, Sands teaches oral administration of the NMDA receptor antagonist, while discussing topical administration only for cases where a patient is unable to swallow or the oral route of administration is otherwise impaired. Systemic administration of NMDA receptor antagonists to treat inner ear disorders is usually ineffective, as the cochlea is protected like the brain by a biological barrier. Relatively high doses to achieve a desired therapeutic effect would thus be required, but various potent side effects of NMDA receptor antagonists such as reduced learning, memory or motility significantly restrict the maximum tolerable doses.

As various studies with humans for the treatment of CNS disorders by NMDA receptor antagonists have shown, plasma levels after systemic administration were consistently below those needed for maximal neuroprotection in animal models, as clinical doses had to be limited due to a number of potentially adverse CNS effects, catatonia, increased blood pressure and anaesthesia Kemp and McKernan, Nature Neuroscience 5, supplement: On the other hand, it has been shown that local administration of the NMDA-AMPA receptor antagonist caroverine to the inner ear results in higher intracochlear concentrations, while avoiding high secondary concentrations in plasma and cerebrospinal fluid as seen with systemic administration Chen et al.

The inventors cite results from a clinical study with systemic administration which showed a reduction in tinnitus during treatment. Hypotheses brought forward to explain the results obtained centre on outer hair cells and the presynapse, and do not specifically cover the role of NMDA receptors. While there are several indications supporting the hypothesis that NMDA receptors play an important role in the genesis of tinnitus induced by cochlear excitotoxicity, the foregoing discussion shows that the molecular mechanisms are still unclear, and that it is therefore not possible to predict reliably whether the use of NMDA receptor antagonists will effectively block this particular type of tinnitus.

Further pathophysiological studies on the generation of tinnitus are thus required to validate the hypothesis and develop specific and truly effective therapeutic strategies. The methods include administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist. In a method for treating tinnitus, the NMDA receptor antagonist administered is effective to suppress or reduce NMDA receptor mediated aberrant activity of the auditory nerve in the human in need of such treatment.

In a method for preventing tinnitus, the NMDA receptor antagonist administered is effective to prevent NMDA receptor mediated aberrant activity of the auditory nerve in the human in need of such treatment.

The present invention also relates to novel methods for the screening of compounds for the treatment and prevention of tinnitus wherein the method utilizes an electrophysiological method of measuring and quantifying the extent of tinnitus. The methods include the administration to a test animal of a test compound wherein the test animal, for example, comprises an electrode in contact with the round window membrane of the ear.

The electrode is used to measure the ensemble spontaneous activity ESA of the ear where a spectral peak at about to Hz is indicative of tinnitus. The administration of test compounds to the animal, to the round window membrane or to the inner ear is embodied in the present invention.

The animal may have acquired tinnitus by, for example, acustic trama, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other equivalent cochlear excitotoxic-inducing occurrence. Hearing loss induced by acoustic trauma was assessed by recording CAP measurements 7 days after trauma. A Acoustic trauma led to a decrease in correct behavioral responses to sound stimulation, followed by partial recovery over time, reflecting the induced hearing loss.

B The number of false positives differed substantially among tested animals following acoustic trauma. Group 1 animals did not experience tinnitus, group 2 animals experienced tinnitus only transiently, while group 3 animals experienced tinnitus both transiently and then permanently.

Treatment with D-JNKI-1 prevented hearing loss after acute acoustic trauma, as shown by the rapid recovery of score following trauma A but had no significant effect on the prevention of tinnitus, as the prevalence and patterns of tinnitus were essentially the same as in untreated animals B.

A The average behavioral score dropped from day 0 to day 1 and recovered subsequently; however improvement was slower than in untreated animals. B Local administration of the NMDA antagonist 7-CK resulted in suppressing persistent tinnitus induced by cochlear excitotoxicity; only cases of transient tinnitus could be observed. A The average behavioral score dropped from day 0 to day 1 and recovered subsequently ; however improvement was slower than in untreated animals.

The stereocilia of OHC and IHC remain intact following salicylate injections over 2 days 6 A , while those animals which were exposed to acoustic trauma display severe damage to OHC stereociliary bundles as well as disarrayed and in some cases even fused indicated by black arrowhead IHC stereocilia 6 D.

Low magnification of the IHC synaptic complex shows no ultrastructural abnormalities in case of the salicylate treatment 6 B , whereas in traumatized animals a massive and dramatic swelling indicated by asterisks of the radial afferent dendrites can be seen at the basal pole of the IHC in the affected frequency range area, confirming that excitotoxicity has occurred 6 E. Note the presence of numerous vacuoles in the apical part of the IHC and abnormally shaped stereocilia indicated by arrowhead.

High magnification of the basal IHC pole shows again no anomalies for the salicylate treated animal 6 C.

The two afferent nerve endings indicated by a1 and a2 are normal, and a characteristic presynaptic body facing afferent a2 is clearly visible. Contrary to this, 6 F displays swollen al and disrupted a2 nerve endings and the presynaptic body facing a2. Immunoblots from the brain of control animals were performed to verify that the molecular weight of the NR1 subunit is identical in both brain and cochlea.

A shows the permanent threshold shift PTS of the auditory function resulting from the exposure to noise at the beginning of the experiment. B shows the ESA recording just prior to the exposure of the animal to dB of sound at 6 kHz during 40 minutes. Note the spectral peak centered at around Hz to 1 kHz which is indicative of a normal hearing activity.

C shows the ESA recording 5 days after the noise exposure on T0. Note the spectral peak in the to frequency range, which is indicative of the presence of tinnitus. This peak had appeared immediately after the noise trauma and persisted from then on in a stable way. The regular spectral peak, however, had disappeared and subsequently recovered.

The contralateral ear showed exactly the same pattern of ESA with a peak at to Hz, indicating also the presence of tinnitus. Following these measurements, the animal was treated on T0 with the NMDA antagonist Ketamine by local administration onto the round window membrane.

D On the day following treatment administration T1 , the ESA recording for the treated ear showed the absence of the to Hz spectral peak, indicating the successful suppression of tinnitus. The regular peak centered at Hz to 1 kHz still appeared, yet diminished.

In the contralateral ear, tinnitus was still measured. In addition, the regular peak centered at around Hz to 1 kHz had fully recovered. F In the untreated left ear, the presence of tinnitus was still indicated by the ESA recording. Please note that the PTS was not changed by the treatment A , i. The present invention is based on experimental findings with an animal model of tinnitus induced by cochlear excitotoxicity.

The invention relates to the use of pharmaceutical compounds that act specifically as NMDA receptor antagonists. While not wishing to be bound by theory, it is believed that an NMDA receptor antagonist of the present invention binds to the NMDA receptor at one of its various binding sites, thereby blocking partly or entirely the opening of the receptor's ion channel. The NMDA receptor is activated in a complex manner such that both glutamate and glycine binding are required to open the ion channel and permit calcium entry Kemp and McKernan, Nature Neuroscience 5, supplement: Glutamate has the neurotransmitter role, as it is released from presynaptic terminals in an activity-dependent manner, whereas glycine acts as a modulator, which is present in the extracellular fluid at more constant levels.

The ion-channel integral to the NMDA receptor is voltage-dependently blocked by magnesium, and depolarization removes this block. Binding of an NMDA receptor antagonist to either of the three antagonist sites results in partial or complete blockage of the NMDA receptor and hence blocks or reduces the opening of the ion channel and depolarization of the neuron. The NMDA receptor antagonist thus suppresses the aberrant excitation of the auditory nerve through up-regulated NMDA receptors which may follow cochlear excitotoxicity and thus also reduces or eliminates the perception of tinnitus.

By targeting specifically NMDA receptors, which are only up-regulated under pathophysiological conditions, to suppress the NMDA receptor mediated aberrant activity of the auditory nerve, undesired side-effects on hearing can be avoided, as normal auditory neurotransmission is primarily mediated by AMPA receptors. In one embodiment, the invention relates to a method for treating tinnitus induced by cochlear excitotoxicity in a human.

The method comprises administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist. The NMDA receptor antagonist is administered in an amount and for a period of time, effective to suppress or reduce NMDA receptor-mediated aberrant activity of the auditory nerve in a human in need of such treatment.